Reported Sunday, Crinetics Presents Up To Two-Year PATHFNDR Open-Label Extension Data At ENDO 2026 Confirming PALSONIFY Maintains Stable IGF-1 Levels And Acromegaly Symptom Control
CRINETICS PHARMACEUTICALS, INC.
CRINETICS PHARMACEUTICALS, INC. CRNX | 0.00 |
- Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms
- Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks
- Additional ENDO highlights include long-term ACROBAT data demonstrating PALSONIFY and cabergoline combination improves biochemical control of acromegaly